Literature summary extracted from
Fontanella, G.H.; De Vusser, K.; Laroy, W.; Daurelio, L.; Nocito, A.L.; Revelli, S.; Contreras, R.
Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate (2008), Vaccine, 26, 2322-2334.
Application
EC Number |
Application |
Comment |
Organism |
---|
3.2.1.18 |
medicine |
mice vaccinated with an engineered enzymatically deficient mutant trans-sialidase containing the catalytic domain without the immunodominant shed acute phase antigen repeats SAPA, are highly protected against Trypanosoma cruzi infection. Adult male BALB/c mice immunized with mutant protein are protected against challenge with a lethal dose of Trypanosoma cruzi trypomastigotes. The protected immunized mice developed no clinical or tissue evidence of infection throughout the study |
Trypanosoma cruzi |
Cloned(Commentary)
EC Number |
Cloned (Comment) |
Organism |
---|
3.2.1.18 |
expression in Pichia pastoris |
Trypanosoma cruzi |
Protein Variants
EC Number |
Protein Variants |
Comment |
Organism |
---|
3.2.1.18 |
additional information |
engineering of an enzymatically deficient mutant trans-sialidase containing the catalytic domain without the immunodominant shed acute phase antigen repeats SAPA. Mice vaccinated with the mutant trans-sialidase are highly protected against Trypanosoma cruzi infection |
Trypanosoma cruzi |
Organism
EC Number |
Organism |
UniProt |
Comment |
Textmining |
---|
3.2.1.18 |
Trypanosoma cruzi |
- |
- |
- |